ERBB2 and breast carcinoma: (16, 20, 43) Moreover, an ongoing DESTINY-Breast06 trial is evaluating the efficacy of T-DXd following one or more lines of endocrine therapy in breast cancers with an “ultra-low” level of HER2 expression categorized by IHC > 0 < 1+; IHC 0 no membrane staining.